Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD.
Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.
J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.
GPRC5D-Targeted CAR T Cells for Myeloma.
Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL.
N Engl J Med. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900.
Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease.
Johansen M, Levring MB, Stokbro K, Diaz-delCastillo M, Khan AA, Wickstroem LA, Gundesen MT, Kristensen IB, Nyvold CG, Andersen MØ, Andersen TL, Abildgaard N, Lund T.
Cancers (Basel). 2023 Nov 25;15(23):5585. doi: 10.3390/cancers15235585.
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL, Martin TG 3rd, Shah N, Vandenberg S, Prakash S, Besse L, Driessen C, Posey AD Jr, Mullins RD, Eyquem J, Wells JA, Wiita AP.
Nat Commun. 2022 Jul 15;13(1):4121. doi: 10.1038/s41467-022-31810-6.
Bisphosphonates: mechanism of action and role in clinical practice.
Drake MT, Clarke BL, Khosla S.
Mayo Clin Proc. 2008 Sep;83(9):1032-45. doi: 10.4065/83.9.1032.
Evaluation of mandibular bone changes in multiple myeloma patients on dental panoramic radiographs.
Akyol R, Şirin Sarıbal G, Amuk M.
Oral Radiol. 2022 Oct;38(4):575-585. doi: 10.1007/s11282-022-00590-6. Epub 2022 Feb 7.
Controversies in the use of new bone-modifying therapies in multiple myeloma.
Terpos E, Ntanasis-Stathopoulos I.
Br J Haematol. 2021 Jun;193(6):1034-1043. doi: 10.1111/bjh.17256. Epub 2020 Nov 29.
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K, Stopeck A.
J Bone Oncol. 2022 Feb 7;33:100416. doi: 10.1016/j.jbo.2022.100416. eCollection 2022 Apr.
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
Dickinson M, Prince HM, Kirsa S, Zannettino A, Gibbs SD, Mileshkin L, O'Grady J, Seymour JF, Szer J, Horvath N, Joshua DE.
Intern Med J. 2009 May;39(5):304-16. doi: 10.1111/j.1445-5994.2008.01824.x. Epub 2008 Nov 3.
